284 related articles for article (PubMed ID: 36900160)
1. Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma.
Major A; Porcu P; Haverkos BM
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900160
[TBL] [Abstract][Full Text] [Related]
2. Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).
Haverkos BM; Coleman C; Gru AA; Pan Z; Brammer J; Rochford R; Mishra A; Oakes CC; Baiocchi RA; Freud AG; Porcu P
Discov Med; 2017 Mar; 23(126):189-199. PubMed ID: 28472613
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Tsuyama N; Asaka R; Dobashi A; Baba S; Mishima Y; Ueda K; Oguchi M; Tsuji H; Hatake K; Takeuchi K
Hematol Oncol; 2018 Feb; 36(1):328-335. PubMed ID: 28695659
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
5. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
6. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.
Wai CMM; Chen S; Phyu T; Fan S; Leong SM; Zheng W; Low LCY; Choo SN; Lee CK; Chung TH; Ban KHK; Ghosh S; Lie S; Kato S; Nakamura S; Takahashi E; Ko YH; Khoury JD; Chuang SS; Au-Yeung RKH; Tan SY; Lim ST; Ong CK; Ho YH; Poon LM; De Mel S; Jeyasekharan AD; Chng WJ; Otto F; Quintanilla-Martinez L; Zanardi F; Iannelli F; Tripodo C; Pitt JJ; Ng SB
Haematologica; 2022 Aug; 107(8):1864-1879. PubMed ID: 35021606
[TBL] [Abstract][Full Text] [Related]
7. Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.
Mundy-Bosse BL; Weigel C; Wu YZ; Abdelbaky S; Youssef Y; Casas SB; Polley N; Ernst G; Young KA; McConnell KK; Nalin AP; Wu KG; Broughton M; Lordo MR; Altynova E; Hegewisch-Solloa E; Enriquez-Vera DY; Dueñas D; Barrionuevo C; Yu SC; Saleem A; Suarez CJ; Briercheck EL; Molina-Kirsch H; Loughran TP; Weichenhan D; Plass C; Reneau JC; Mace EM; Gamboa FV; Weinstock DM; Natkunam Y; Caligiuri MA; Mishra A; Porcu P; Baiocchi RA; Brammer JE; Freud AG; Oakes CC
Blood Cancer Discov; 2022 Mar; 3(2):154-169. PubMed ID: 35247900
[TBL] [Abstract][Full Text] [Related]
8. Extranodal NK/T-Cell Lymphoma, Nasal Type: Genetic, Biologic, and Clinical Aspects with a Central Focus on Epstein-Barr Virus Relation.
Takahara M; Kumai T; Kishibe K; Nagato T; Harabuchi Y
Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34202088
[TBL] [Abstract][Full Text] [Related]
9. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
[TBL] [Abstract][Full Text] [Related]
10. Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.
Liang JH; Wang WT; Du KX; Xing TY; Wang Y; Wang H; Liu L; Guo R; Shao Y; Liang J; Li Y; Shen HR; Wang L; Li JY; Xu W
Hum Cell; 2023 Mar; 36(2):835-846. PubMed ID: 36520345
[TBL] [Abstract][Full Text] [Related]
11. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
12. The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins.
Wang Y; Tan H; Yu T; Ma X; Chen X; Jing F; Zou L; Shi H
BMC Cancer; 2021 Dec; 21(1):1303. PubMed ID: 34872521
[TBL] [Abstract][Full Text] [Related]
13. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).
Rong Q; Gao Y; Cai Q; Wang X; Bai B; Ping L; He H; Rao H; Zhang Y; Li Z; Cai Q; Jiang W; Huang H
Expert Rev Anticancer Ther; 2021 Jan; 21(1):121-127. PubMed ID: 33397158
[No Abstract] [Full Text] [Related]
14. The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.
de Mel S; Soon GS; Mok Y; Chung TH; Jeyasekharan AD; Chng WJ; Ng SB
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966370
[TBL] [Abstract][Full Text] [Related]
15. The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.
Kim H; Ko YH
Life (Basel); 2022 Jan; 12(1):. PubMed ID: 35054466
[TBL] [Abstract][Full Text] [Related]
16. [Extra-nodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous and ocular involvement].
Marzouki-Zerouali A; Charbit L; Mitcov M; Violon F; Schmutz JL; Moawad S; Bursztejn AC
Ann Dermatol Venereol; 2019 Oct; 146(10):626-633. PubMed ID: 31371036
[TBL] [Abstract][Full Text] [Related]
17. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract][Full Text] [Related]
18. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
19. Extranodal natural-killer/T-cell lymphoma, nasal type: An immunomorphological study from a regional cancer institute in India.
Agrawal M; Champaka G; Amirtham U; Jacob LA; Premalata CS
J Cancer Res Ther; 2022; 18(4):1137-1143. PubMed ID: 36149173
[TBL] [Abstract][Full Text] [Related]
20. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
